Eli Lilly and Company
893 S Delaware St
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We also have been committed to investing in our employees – through competitive salaries, training and development, health, and the opportunity to do good. The pharmaceutical industry is a complex, rapidly changing environment and we’re looking for people who are determined to make life better for people around the world. Visit https://careers.lilly.com for more information.
Stock Symbol: LLY
Stock Exchange: NYSE
We discover life-changing medicines. We commit to diversity and inclusion. We volunteer millions of hours. We make life better. We are Lilly.
2244 articles with Eli Lilly and Company
Under the agreement, Lilly gains non-exclusive commercial rights for application of the technology to the development of proprietary products.
According to a BioSpace Community Survey, almost 70% of life sciences professionals plan to look for a new job in the next 12 months. Don't delay, accelerate your job search and check out top companies who are looking for quality candidates in 2019!
Eli Lilly and Co. has licensed 2G UNic technology from Leiden, the Netherlands-based ProteoNic Biotechnology BV. The tech is used to improve recombinant protein production. No financial details were disclosed.
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Eli Lilly and Company and Incyte Corporation announced today that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis.
Messenger RNA (mRNA) is a family of RNA molecules that transport genetic information from DNA to the ribosome, where it specifies the amino acid sequence that creates proteins. In theory, by coding your own mRNA, it should be possible to insert it into the cells and turn them into protein factori...
The two Phase III trials are part of a five-trial package the companies are conducting to support potential regulatory approval for this indication.
Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction
Eli Lilly and Company and Loxo Oncology, Inc. announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Lilly's previously-announced tender offer to acquire all outstanding shares of Loxo Oncology for a purchase price of $235.00 per share in cash, or approximately $8.0 billion.
FDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer
New approval based on Phase 3 KEYNOTE-189 results
Eli Lilly and Company (NYSE: LLY) has revised the date for its fourth-quarter and full-year 2018 financial results announcement.
Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain.
1/29/2019Pfizer and Eli Lilly and Co. announced that their tanezumab hit two out of three co-primary endpoints in one dose and all three with a higher dose in patients with moderate-to-severe osteoarthritis (OA) pain in a Phase III trial.
1/25/2019On Thursday, regulators with both the FDA and EMA announced that patients prescribed the drug should ask their doctors if it is wise to continue taking it. This comes after Lartruvo failed to hit endpoints in a Phase III study of advanced or metastatic soft tissue sarcoma.
It’s no secret that the pharmaceutical industry spends a significant amount of money lobbying state and federal governments to gain leverage that will benefit individual companies and the industry overall.
Government Employees Affected by Federal Shutdown Encouraged to Contact Lilly Diabetes Solution Center to Access Insulin
Eli Lilly and Company (NYSE: LLY) is encouraging government employees affected by the partial government shutdown to call the Lilly Diabetes Solution Center and check whether they are receiving all eligible discounts to lower the out-of-pocket costs for their Lilly insulin.
In October, the Minnesota Attorney General filed a lawsuit against three of the biggest insulin manufacturers over price gouging claims. One month later the American Diabetes Association published recommendations and public policy solutions.
Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients
REACH-2 is the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population known for poor prognosis
Study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population; there was no difference in survival between the study arms for either population.
Eli Lilly’s ANNOUNCE Phase III clinical trial of Lartruvo (olaratumab) in advanced or metastatic soft tissue sarcoma failed to meet the primary endpoints of overall survival.
The two companies inked a non-disclosure agreement on December 22, 2018 and amended it a day later. One of the things apparent is that the companies wanted to make a splash at the JPM conference.
Zymeworks Reports Second Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration
- Lilly’s second immune-oncology candidate using Zymeworks’ novel Azymetric™ platform to start clinical trials - Zymeworks to receive milestone payment of US$8.0 million for this second IND submission - Lilly is one of eight pharma partners; INDs by others anticipated - Total value of remaining potential milestones for all Zymeworks’ partnerships exceeds US$7.6 billion